FATE
Fate Therapeutics Inc

6,384
Mkt Cap
$129.19M
Volume
1.41M
52W High
$1.94
52W Low
$0.661
PE Ratio
-0.85
FATE Fundamentals
Price
$1.09
Prev Close
$1.12
Open
$1.13
50D MA
$1.09
Beta
1.70
Avg. Volume
1.8M
EPS (Annual)
-$1.64
P/B
0.55
Rev/Employee
$75,309.39
$6.22
Loading...
Loading...
News
all
press releases
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average - What's Next?
Fate Therapeutics (NASDAQ:FATE) Stock Passes Above 50 Day Moving Average - Time to Sell...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have received a consensus recommendation of "Hold" from the nine analysts that are covering the firm, Marketbeat.com reports. One...
MarketBeat·10d ago
News Placeholder
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets PR Newswire...
PR Newswire·16d ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50 Day Moving Average - Should You Sell...
MarketBeat·22d ago
News Placeholder
Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) insider Cindy Tahl sold 10,589 shares of the business's stock in a transaction dated Friday, January 9th. The shares were sold at an average...
MarketBeat·29d ago
News Placeholder
Insider Selling: Fate Therapeutics (NASDAQ:FATE) Insider Sells 10,589 Shares of Stock
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) insider Cindy Tahl sold 10,589 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average...
MarketBeat·30d ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have received a consensus recommendation of "Hold" from the nine ratings firms that are currently covering the firm, Marketbeat...
MarketBeat·1mo ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving Average - Here's Why
Fate Therapeutics (NASDAQ:FATE) Stock Passes Below 200 Day Moving Average - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving Average - What's Next?
Fate Therapeutics (NASDAQ:FATE) Shares Cross Below Two Hundred Day Moving Average - Here's Why...
MarketBeat·2mo ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are covering the firm, MarketBeat Ratings reports. One equities...
MarketBeat·2mo ago
<
1
2
...
>

Latest FATE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.